Background illustration for clinical trials search

Paid Clinical Trials Olathe

Discover 707 paid clinical trials in Olathe, Kansas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 707

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

for

Chronic Kidney Disease and Hypertension

Location: Kansas City KS, Kansas City MO, Wichita KS,

Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT06742723

Phase3, Recruiting

Study of ATX-01 in Participants With DM1

for

Myotonic Dystrophy 1

Location: Fairway KS, Iowa City IA, Richmond VA, Gainesville FL,

Sponsor: ARTHEx Biotech S.L.

Sex: All

Age: 18 - 64

Code: NCT06300307

Phase1, Phase2, Recruiting

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

for

Relapsing Multiple Sclerosis

Location: Overland Park KS, St Louis MO, Iowa City IA,

Sponsor: TG Therapeutics, Inc.

Sex: All

Age: 18 - 65

Code: NCT05877963

Phase3, Recruiting

Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

for

Chronic Inflammatory Demyelinating Polyneuropathy

Location: Kansas City KS, Yukon OK, Chicago IL, Milwaukee WI,

Sponsor: Immunovant Sciences GmbH

Sex: All

Age: 18+

Code: NCT07032662

Phase2, Recruiting

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

for

Relapsing Multiple Sclerosis, Multiple Sclerosis

Location: Roeland Park KS, Lincoln NE, Omaha NE, Norman OK,

Sponsor: TG Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06433752

Recruiting

Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas

for

Peripheral T-cell Lymphoma

Location: Westwood KS, Dallas TX, Louisville KY, Atlanta GA,

Sponsor: CerRx, Inc.

Sex: All

Age: 18+

Code: NCT02495415

Phase2, Recruiting

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

for

Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer,

Location: Westwood KS, St Louis MO

Sponsor: Washington University School of Medicine

Sex: All

Age: 18+

Code: NCT06374459

Phase1, Phase2, Recruiting

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

for

Solid Tumor

Location: Westwood KS, Iowa City IA, Houston TX, Detroit MI,

Sponsor: Sanofi

Sex: All

Age: 18+

Code: NCT05584670

Phase1, Phase2, Recruiting

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

for

Non-Small Cell Lung Cancer

Location: Westwood KS, Kansas City MO, Omaha NE, St Louis MO,

Sponsor: Summit Therapeutics

Sex: All

Age: 18+

Code: NCT05899608

Phase3, Recruiting

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

for

Breast Cancer

Location: Westwood KS, Kansas City MO, Sioux Falls SD,

Sponsor: Exact Sciences Corporation

Sex: All

Age: 18+

Code: NCT06401421

Recruiting

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

for

Myeloproliferative Neoplasms

Location: Westwood KS, St Louis MO, Nashville TN, Houston TX,

Sponsor: Incyte Corporation

Sex: All

Age: 18+

Code: NCT06034002

Phase1, Recruiting

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

for

B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy,

Location: Westwood KS, St Louis MO, San Antonio TX,

Sponsor: CRISPR Therapeutics AG

Sex: All

Age: 18+

Code: NCT05643742

Phase1, Phase2, Recruiting

A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)

for

Head and Neck Squamous Cell Carcinoma

Location: Westwood KS, Springfield MO, St Louis MO, Peoria IL,

Sponsor: Tempus AI

Sex: All

Age: 18+

Code: NCT06163534

Recruiting

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

for

Advanced Melanoma

Location: Westwood KS, Minneapolis MN, Chicago IL, Dallas TX,

Sponsor: Immunocore Ltd

Sex: All

Age: 18+

Code: NCT06112314

Phase3, Recruiting

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

for

Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis,

Location: Westwood KS, Lincoln NE, Des Moines IA, Dallas TX,

Sponsor: Kartos Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06479135

Phase3, Recruiting

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

for

AL Amyloidosis

Location: Westwood KS, Kansas City KS, Bellevue NE, Omaha NE,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT06022939

Phase3, Recruiting

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

for

Melanoma

Location: Westwood KS, Omaha NE, Tulsa OK, St Louis MO, Peoria IL,

Sponsor: Regeneron Pharmaceuticals

Sex: All

Age: 18+

Code: NCT06246916

Phase3, Recruiting

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

for

NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer,

Location: Westwood KS, Waukee IA, St Louis MO, Iowa City IA,

Sponsor: Revolution Medicines, Inc.

Sex: All

Age: 18+

Code: NCT06881784

Phase3, Recruiting

Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC

for

NSCLC Stage IV, NSCLC, Recurrent

Location: Kansas City KS

Sponsor: University of Kansas Medical Center

Sex: All

Age: 18+

Code: NCT04467723

Phase1, Phase2, Recruiting

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

for

Non Hodgkin Lymphoma,

Location: Westwood KS, Chicago IL, Dallas TX, Milwaukee WI,

Sponsor: Miltenyi Biomedicine GmbH

Sex: All

Age: 18+

Code: NCT06116110

Recruiting

Paid Clinical Trials Olathe

Filter results

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

Study of ATX-01 in Participants With DM1

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

Interested in new trials?

Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU